首页> 外文OA文献 >Pharmacological profile and clinical efficacy of human anti-human PD-1 antibody nivolumab (OPDIVO®) as a new immune checkpoint inhibitor

【2h】

Pharmacological profile and clinical efficacy of human anti-human PD-1 antibody nivolumab (OPDIVO®) as a new immune checkpoint inhibitor

机译：人抗人PD-1抗体Nivolumab（Opdivo ®）作为新的免疫检查点抑制剂的药理分布及临床疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Takao Yoshida; Kenichi Koda; Shintaro Nakao; Yukiya Ohyama;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab [J] . Bernhard Roither, Chris Oostenbrink, Wolfgang Schreiner BMC Bioinformatics . 2020,第17期

机译：免疫检查点的分子动力学编程细胞死亡蛋白I，PD-1：BC环的构象变化在配体PD-L1和单克隆抗体Nivolumab的结合时
2. A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer [J] . Zhongyuan Fan, Ye Liang, Xuecheng Yang, OncoTargets and therapy . 2019,第1期

机译：PD-1 / PD-L1免疫检查点抑制剂作为转移性膀胱癌治疗的疗效和安全性的荟萃分析
3. Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination ChemotherapyPrevious Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy [J] . Harada Daijiro, Takata Kenji, Mori Shunta, Anticancer Research: International Journal of Cancer Research and Treatment . 2019,第9期

机译：以往的免疫检查点抑制剂治疗，增加多西紫杉醇和拉姆梭拉组合组合化疗的疗效术治疗免疫检查点抑制剂治疗，增加了多西紫杉醇和拉姆索姆拉姆联合化疗的疗效
4. Molecular dynamics of the immune checkpoint Programmed Cell Death Protein I, PD-1: Conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab [C] . Bernhard Roither, Chris Oostenbrink, Wolfgang Schreiner IEEE International Conference on Bioinformatics and Biomedicine . 2019

机译：免疫检查点的分子动力学程序性细胞死亡蛋白I，PD-1：配体PD-L1与单克隆抗体nivolumab结合后BC环的构象变化
5. Understanding How Adrenergic Stress Signaling Impacts the Anti-Tumor Immune Response and the Efficacy of Checkpoint Inhibitors in Murine Tumor Models [D] . Bucsek, Mark Joseph. 2019

机译：了解肾上腺素能应激信号如何影响抗肿瘤免疫应答以及检查点抑制剂在鼠肿瘤模型中的疗效
6. Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma [O] . Lisa A. Raedler 2015

机译：Opdivo（Nivolumab）：第二种PD-1抑制剂因不可切除或转移性黑素瘤获得FDA批准
7. Pharmacological properties and clinical efficacy of ipilimumab, human anti-human CTLA-4 monoclonal antibody (YERVOY®) [O] . Manabu Amano, Hiroko Kobayashi, Mayumi Hasegawa, 2016

机译：IPILIMIMAB，人抗人CTLA-4单克隆抗体（YEVOY ^{®）的药理性质和临床疗效}

Pharmacological profile and clinical efficacy of human anti-human PD-1 antibody nivolumab (OPDIVO®) as a new immune checkpoint inhibitor

著录项

引文网络

相似文献

相关主题

期刊订阅